Who
Margaret M. FitzPatrick
Director
Company insider
Files Form 4 as: Director, AN2 Therapeutics; Director, Vistagen Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 2
- Sells
- 0
- Bought
- $33K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 21 Jul 2021
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Bought | $12K2,098 at $5.53 | filing |
| 1 Sep 2026filed 2 Sep 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Bought | $12K2,098 at $5.53 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,463 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,463 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,463 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,463 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,362 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,742 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —23,742 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,600 at $0.00 | filing |
| 28 May 2025filed 29 May 2025 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K8,610 at $1.18 | filing |
| 22 May 2025filed 23 May 2025 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,111 at $0.00 | filing |
| 6 Sep 2024filed 10 Sep 2024 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,100 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.